Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 peptide immunotherapy plus standard treatment in malignant glioma
jRCTs061180085Phase 2Recruiting
- Sponsor
- NEC Corporation
- Start
- Sep 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1-W10 peptide and temozolomide in malignant glioma and glioblastoma (GBM), sponsored by NEC Corporation. Primary endpoints: Safety and side effects and Progression-free survival. Started Sep 2010; status: recruiting.
02
Drugs
WT1-W10 peptidetemozolomide
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs061180085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180085.